Marker Therapeutics Q2 net income $2.5M; Cell Ready deal extends cash runway into Q4 2025

Marker Therapeutics, Inc.

2023-Q2 EPS reported -$0.28 revenue$1,996,995

Net income of $2.5M vs net loss of $9.2M in Q2 2022; cash and equivalents $18.1M.
Non-dilutive agreement with Cell Ready provides ~$19M cash and reduces annual operating expenses by ~$11M.
Appointed Juan Vera as CEO and Monic Stuart as CMO to lead restructuring and clinical advancement.
NIH awarded $2M SBIR grant for MT-401 AML program; EMA granted Orphan Drug Designation for MT-401.
First lymphoma patient dosed with MT-601 in Phase 1 APOLLO trial with no treatment-related adverse events.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Marker Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the second quarter ended June 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-091425

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.